Radim Němeček

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka et al. · Annals of Oncology · 2015 · 163 citations · Full text

Oncology, Pancreatic Cancer, Clinical Trials +8

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study

Tamas Hickish, Thierry André, Lucjan Wyrwicz et al. · The Lancet Oncology · 2017 · 153 citations

Novel Antibody Treatment, Medicine, Immunology +7

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

Jitka Mlčochová, Petra Vychytilova‐Faltejskova, Manuela Ferracin et al. · Oncotarget · 2015 · 74 citations · Full text

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

Laura Lupini, Cristian Bassi, Jitka Mlčochová et al. · BMC Cancer · 2015 · 59 citations · Full text

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study

Susanna Hegewisch-Becker, Guillermo Méndez, Joseph Chao et al. · Journal of Clinical Oncology · 2024 · 46 citations · Full text